Interleukin - 9 (IL - 9) is an important cytokine in immune system. Recent years, some studies found that IL-9 may be involved in certain types of lymphomas. But until now, similar results have not been reported in B-linked lymphomas. Our previous study indicated that patients with diffuse large B cell lymphoma (DLBCL) had higher serum levels of IL -9 than healthy donors. The receptor of IL -9 (IL – 9R) was detected in DLBCL cell lines as well as biopsy tissues, and the expression of IL – 9R was closely related to the patient's prognostic indicators. Based on these results, we speculate that IL - 9 may be related to the pathogenesis and prognosis of DLBCL. This study intends to expand the clinical sample size and makes further analysis between IL-9 and clinical manifestations, treatment effect and clinical prognosis in DLBCL patients. At the same time, we plan to test the effect of IL - 9 on biological behaviors of DLBCL cells and explore its possible mechanism using gene chip and RNA interference. All the results will be useful for looking for new biomarkers of DLBCL and provide potential therapeutic targets for DLBCL patients.
白介素-9(IL-9)是免疫调节系统的重要细胞因子,近年来的研究发现它可能与某些淋巴瘤的发生发展存在一定关系,但其在B系淋巴瘤中的作用尚未有相关报道。我们的前期研究发现,弥漫大B细胞淋巴瘤(DLBCL)患者血清中IL-9浓度升高,而IL-9受体(IL-9R)则表达于DLBCL细胞株及患者的肿瘤组织中,且表达强度与患者的临床预后指标密切相关,提示IL-9可能与DLBCL的发病及预后具有一定的相关性。本研究拟扩大样本数量,进一步分析IL-9与DLBCL患者临床表现、治疗效果及生存预后的相关性。同时开展细胞株体外试验,研究IL-9对DLBCL细胞生物学行为的影响,并利用基因芯片、RNA干扰等实验技术,对IL-9的作用机制进行探索,为DLBCL寻找新的分子生物学指标及临床治疗靶点提供理论及实验依据。
弥漫性大B细胞淋巴瘤(DLBCL)是最常见的成人非霍奇金淋巴瘤(NHL)类型,约占所有NHL的30%。随着治疗方案的不断进展, DLBCL患者的5年生存率提高到了接近60%,但是,仍有大约三分之一的患者最终死于耐药或疾病复发)。分子生物学病因的不明确,限制了DLBCL治疗的进一步发展。.白介素-9(IL-9)是免疫调节系统的重要细胞因子,近年来的研究发现它可能与某些淋巴瘤的发生发展存在一定关系,但其在B系淋巴瘤中的作用尚未有相关报道。.本项目研究了弥漫大B细胞淋巴瘤(DLBCL)患者血清中IL-9的浓度,并与患者临床资料进行相关性分析,证实了初诊DLBCL患者血清IL-9浓度升高,切IL-9的升高与患者的临床预后相关,为临床DLBCL患者的治疗及预后评估提供了新的分子指标。.同时,我们在体外细胞学试验中直接用IL-9作用DLBCL细胞株LY1及LY8,直接的证实了IL-9对DLBCL的促进增殖及抑制凋亡的作用,为它的临床作用提供了直接的基础实验证据。我们还利用最先进的全基因组测序技术,对IL-9干预过的细胞株进行全基因组测序,包括smallRNA、microRNA、linkRNA等,与正常细胞基因组进行比对,筛选了部分差异表达及调控的miRNA片段,预测了新的microRNA分子,这更深入探索了IL-9作用的分子机制,为将来进一步的研究提供了大数据的支持。
{{i.achievement_title}}
数据更新时间:2023-05-31
The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects
视网膜母细胞瘤的治疗研究进展
Novel alternative splicing of GABA receptor RDL exon 9 fromLaodelphax striatellusmodulates agonist potency
Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia
PI3K-AKT-mTOR通路对骨肉瘤细胞顺铂耐药性的影响及其机制
PKCδ表达与弥漫大B细胞淋巴瘤疗效和预后的相关性及其机制研究
EpCAM介导弥漫大B细胞淋巴瘤免疫逃逸的机制研究
弥漫大B细胞淋巴瘤中LMP1癌基因下调B细胞终末分化调控因子Blimp1基因的作用机制及预后预测研究
miRNA-34在弥漫大B细胞淋巴瘤发病机制中的作用研究